TFR

Trading

Floor Research



This Trading Floor Research report contains:

• Terns Pharmaceuticals Inc. (TERN) is offering another chance to add to the existing position.




This Trading Floor Research report is the weekly follow-up:

(Please, watch this list closely. If a TFR recommended stock does not appear in this list, it has been sold or was never bought)

Terns Pharmaceuticals Inc. (TERN) has been trading above its critical Fibonacci number at 9.50 for the past four sessions. After hitting a high of 10.67 yesterday, it is throwing back into its trendline. A 30-minute close above 10.08 on increased volume will offer another chance to accumulate shares. (Refer to the TERN writeup)

Follow-on buy candidate: Terns Pharmaceuticals Inc. (TERN)

- Industry Group: Medical Biomed/Biotech. The group currently ranks as the 17th strongest industry group in the market out of 197 and is up +3.78% YTD. Medical Biomed/Biotech gave its most recent buy signal on November 10, 2022.
- Terns Pharmaceuticals Inc. (TERN) develops molecularly targeted drugs for treating liver disease and cancer.
- Terns Pharmaceuticals Inc. (TERN) is at the top of its recent trading range and ready to break out of its base. This week's price action on heavy volume is telegraphing a massive move higher. The stock is offering another opportunity to add to existing shares.
- Terns Pharmaceuticals Inc. (TERN) will confirm adding to the position with a 30-minute close above 10.08 on heavy volume.
- Increase the position to 3-stars(***).
- Under massive institutional accumulation with a Daily Up/Down Volume ratio of 3.83.
- Terns Pharmaceuticals Inc. (TERN) closed at 9.88.
- Terns Pharmaceuticals Inc. (TERN) VWAP is at 8.26
- Sell target prices: 1st target is 11.74; 2nd target is 14.43; 3rd target is 15.67; 4th target is 22.04-22.42
- Stop sell price: Close below 9.50.





This Trading Floor Research report is the weekly follow-up:

(Please, watch this list closely. If a TFR recommended stock does not appear in this list, it has been sold or was never bought)

- Gaotu Techedu Inc. CL A (GOTU) was sold today. Chinese stocks gave a sell signal, and most are losing momentum.
- Borr Drilling Limited (BORR) hit a new high today at 16.25 and came very close to Fibonacci resistance at 6.32. The Energy sector is showing weakness but has not given a sell signal. The Oil & Gas Drilling group is showing incredible strength, closing at new highs today. Oil Drilling stocks are the only industry group I would own energy stocks at this time.
- Atour Lifestyle Holdings Limited ADR (ATAT) was sold today with a nice profit. Chinese stocks gave a sell signal, and
 most are losing momentum.
- Sunlands Technology Group ADS (STG) was sold today with a nice profit. Chinese stocks gave a sell signal, and most are losing momentum.




This Trading Floor Research report is the weekly follow-up:

(Please, watch this list closely. If a TFR recommended stock does not appear in this list, it has been sold or was never bought)


- Olympic Steel Inc. (ZEUS) was bought at 40.53 and hit a new high this week at 49.00. The strength in the Steel Producers industry group will push this stock higher. The next Fibonacci target is at 52.65.
- **ProShares UltraPro Russell 2000 (URTY)** gave a 30-minute confirmation last week at 49.10. The ETF rallied to 54.68 but has been pulling back as the market weakens.
- **Direxion Daily S&P Biotech Bull 3X (LABU)** gave a 30-minute confirmation last week at 8.43. Today it sold off to close at 7.79 following a very weak market. Market weakness is affecting the Biotech industry group. My stop on LABU is at 7.70.





¹The results are not (or may not be) representative of the performance of all selections made by Trading Floor Research (TFR) newsletter. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice.





Disclaimer

Before using this site, please make sure that you note the following important information:

Do your Own Research

Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find on our Website and wish to rely upon, whether for the purpose of making an investment decision or otherwise.

The content of this email is confidential and intended for the recipient specified in message only. It is strictly forbidden to share any part of this message with any third party, without a written consent of the sender. If you received this message by mistake, please reply to this message and follow with its deletion, so that we can ensure such a mistake does not occur in the future